News Feeds

March trial for Desai may be postponed again
Las Vegas Review - Journal
By Jeff German Dr. Dipak Desai may have been found competent to face criminal charges in the hepatitis C outbreak, but his upcoming March 12 trial is expected to be delayed again. Lawyers on both sides of the massive criminal case do not want to talk ...
FOX5 Vegas - KVVUDipak Desai found mentally fit to stand trialKVVU Las Vegas

all 5 news articles »

RTT News
Gilead Rises on Hepatitis C Trial Results: San Francisco Mover
BusinessWeek
3 (Bloomberg) -- Gilead Sciences Inc., the drugmaker that acquired Pharmasset Inc. last month for its experimental hepatitis C treatments, gained the most in three years after one of the medicines produced positive clinical trial results.
Gilead Sciences jumps on hepatitis C dataCBS News
Gilead Woes With New Hep C Data, Boxing Out Poor 2012 GuidanceTheStreet.com
An all-oral hepatitis C drug may be one step closer to realityLagonian.com
FierceBiotech -Wall St. Cheat Sheet
all 64 news articles »

AsianWeek
White House Pledges Support to End Viral Hepatitis
AsianWeek
1, the White House Initiative on Asian Americans and Pacific Islanders expressed their commitment to ending viral hepatitis nationwide. 1 in 12 people worldwide is living with viral hepatitis, with viral hepatitis affecting as many as 5 million ...

Financial Times
Big pharma tipped as tonic for investors
Financial Times
In early January, Bristol-Myers Squibb agreed to pay $26 a share to gain control of hepatitis C drug developer Inhibitex – a 163 per cent premium to its share price before the deal. It led to an immediate jump in the share prices of two other groups ...

and more »

New York Times (blog)
Adults Still Slow to Get Their Shots
MedPage Today
Note also that vaccination coverage estimates for the three vaccines in this report that are included in Healthy People 2020 (pneumococcal, herpes zoster, and hepatitis B) are well below their respective target levels. With three exceptions, coverage ...
New Vaccine Recommendations for Boys and DiabeticsNew York Times (blog)
US recommends routine HPV vaccination for boysAFP
HPV Vaccine for Boys Urged By CDCABC News (blog)
KDRV
all 61 news articles »

Alanine Aminotransferase Levels ID Liver Disease Risk
Doctors Lounge
Alanine aminotransferase levels can be used to discriminate between individuals infected with hepatitis C virus RNA and those at low risk for liver disease, according to a study published in the February issue of Hepatology. FRIDAY, Feb.

and more »

AFP
US recommends routine HPV vaccination for boys
AFP
Other changes as part of an annual update to US immunization schedules included a recommended hepatitis B vaccine to the protect the livers of adults up to age 60 who have diabetes and a vaccine against whooping cough for pregnant women.
New Vaccine Recommendations for Boys and DiabeticsNew York Times (blog)
Vaccines: They're Not Just for Kids (But Too Few US Adults Are Getting Immunized)TIME
HPV Vaccine for Boys Urged By CDCABC News (blog)
Nurse.com
all 42 news articles »

Citybizlist
Idenix Says FDA Lifts Partial Hold On Hepatitis Drug IDX184; But Stock Down
NASDAQ
(RTTNews.com) - Idenix Pharmaceuticals Inc. (IDIX) said Friday that the US Food and Drug Administration has lifted the partial hold placed on its lead candidate IDX184 for the treatment of Hepatitis C Virus, or HCV. The FDA decision will allow Idenix ...
Idenix Falls Casualty to Gilead Hep C HooplaTheStreet.com
Idenix gets good news on hep C trial, but can't compete with GileadFierceBiotech
Idenix: FDA lifts partial hold on hepatitis C drugMarketWatch
Mass High Tech -Sacramento Bee
all 31 news articles »

Bloomberg
Dow Rallies to Highest Level Since 2008 on Jobs Report
Bloomberg
Gilead Sciences Inc. surged 9.1 percent on positive data from an experimental hepatitis C drug. The Standard & Poor's 500 Index rose 1.3 percent to 1342.27 at 10:22 am New York time. The benchmark gauge has climbed 2 percent since Jan.

and more »

Citybizlist
Idenix Falls Casualty to Gilead Hep C Hoopla
TheStreet.com
(TheStreet) -- Idenix Pharmaceuticals(IDIX) shares fell Friday on worries that its lead hepatitis C drug can't compete against a rival drug from Gilead Sciences(GILD). US regulators actually delivered good news to Idenix Friday: Lifting a clinical hold ...
Idenix Says FDA Lifts Partial Hold On Hepatitis Drug IDX184; But Stock DownNASDAQ
Idenix gets good news on hep C trial, but can't compete with GileadFierceBiotech
Idenix: FDA lifts partial hold on hepatitis C drugMarketWatch
Mass High Tech -Sacramento Bee
all 31 news articles »

Dow Average Rallies to Highest Level Since 2008 on Jobs Report
BusinessWeek
Gilead Sciences Inc. surged 9.1 percent on positive data from an experimental hepatitis C drug. The Standard & Poor's 500 Index rose 1.3 percent to 1342.27 at 10:22 am New York time. The benchmark gauge has climbed 2 percent since Jan.

and more »

RTT News
Gilead Rises on Hepatitis C Trial Results: San Francisco Mover
BusinessWeek
3 (Bloomberg) -- Gilead Sciences Inc., the drugmaker that acquired Pharmasset Inc. last month for its experimental hepatitis C treatments, gained the most in three years after one of the medicines produced positive clinical trial results.
Gilead Sciences jumps on hepatitis C dataCBS News
Gilead Woes With New Hep C Data, Boxing Out Poor 2012 GuidanceTheStreet.com
An all-oral hepatitis C drug may be one step closer to realityLagonian.com
FierceBiotech -Wall St. Cheat Sheet
all 60 news articles »

Citybizlist
Idenix gets good news on hep C trial, but can't compete with Gilead
FierceBiotech
Idenix put out the news this morning that the FDA had lifted a partial hold on its hepatitis C drug IDX184--and then watched its share price slide. In a sign of just how volatile the whole hepatitis C arena has become after back-to-back blockbuster ...
Idenix Announces Removal of the Partial Clinical Hold on HCV Nucleotide ...Sacramento Bee
About IDX184 Partial Clinical HoldVirtual Press Office (press release)

all 20 news articles »

Gilead Gains on Positive Data From Experimental Hepatitis C Drug
BusinessWeek
2 (Bloomberg) -- Gilead Sciences Inc., the drugmaker that acquired Pharmasset Inc. last month for its experimental hepatitis C treatments, gained in extended trading after saying one of the therapies produced positive clinical trial results.
Gilead Woes With New Hep C Data, Boxing Out Poor 2012 GuidanceTheStreet.com
An all-oral hepatitis C drug may be one step closer to realityLagonian.com
Gilead shares surge as hep C drug scores a cure for big patient populationFierceBiotech
Seeking Alpha
all 7 news articles »

Gilead Woes With New Hep C Data, Boxing Out Poor 2012 Guidance
TheStreet.com
(TheStreet) --Gilead Sciences(GILD) surprised investors Thursday night with exciting new data from its lead hepatitis C drug that overshadowed a disappointing fourth-quarter earnings and weaker-than-expected guidance for the coming year.
Gilead Gains on Positive Data From Experimental Hepatitis C DrugBusinessWeek
Gilead Sciences' CEO Discusses Q4 2011 Results - Earnings Call TranscriptSeeking Alpha

all 4 news articles »

Township hosting hepatitis B vaccine clinics
West Milford Messenger
WEST MILFORD — Hepatitis is one of the most harmful diseases one can have, many times leading into liver cancer years down the road. The West Milford Health Department is promoting a series of three hepatitis B vaccines to protect your liver from this ...

Dismal State of Hepatitis B Management in Country
AllAfrica.com
But in spite, I find it compelling to call attention to the dangerous state of medical knowledge in Nigeria, as experienced in the last three years of battling a chronic disease called Hepatitis B. Without prejudice to my respect for professionals in ...

New York Times (blog)
New Vaccine Recommendations for Boys and Diabetics
New York Times (blog)
In addition to the change in HPV vaccinations in the new schedule, health officials recommended that people with Type 1 or 2 diabetes be vaccinated against hepatitis B. The hepatitis vaccine has been recommended for a number of years for people at risk ...
Adults Still Slow to Get Their ShotsMedPage Today
US recommends routine HPV vaccination for boysAFP
HPV Vaccine for Boys Urged By CDCABC News (blog)
TIME
all 48 news articles »

Las Vegas Sun
Judge: Dipak Desai competent to stand trial in hepatitis case
Las Vegas Sun
By Dave Toplikar (contact) A Clark County district judge ruled Thursday that Dipak Desai, the former high-profile Las Vegas physician at the heart of the hepatitis scare four years ago, is competent to stand trial. Clark County District Judge Kathleen ...
Judge rules ex-doctor competent to stand trial on felony charges in Las Vegas ...The Republic
Prosecutor says doctor in hepatitis C outbreak is faking disabilities.Las Vegas Review - Journal
Desai found competent to stand trialLas Vegas Review-Journal

all 15 news articles »

Gilead Gains on Positive Data From Experimental Hepatitis C Drug
BusinessWeek
2 (Bloomberg) -- Gilead Sciences Inc., the drugmaker that acquired Pharmasset Inc. last month for its experimental hepatitis C treatments, gained in extended trading after saying one of the therapies produced positive clinical trial results.
Gilead Sciences' CEO Discusses Q4 2011 Results - Earnings Call TranscriptSeeking Alpha

all 3 news articles »